A Study of APTO-253 in Patients With Relapsed or Refractory AML or MDS
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Rafael Bejar, MD., PhD.
Aptose Biosciences Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
13 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of Arizona Cancer Center
Tucson, Arizona, United States
- Uc San Diego Moores Cancer Center
La Jolla, California, United States
- University of California, Irvine
Orange, California, United States
- Emory University; Winship Cancer Institute
Atlanta, Georgia, United States
- Ochsner Cancer Institute
New Orleans, Louisiana, United States
- University of Michigan
Ann Arbor, Michigan, United States
- St. Vincent Frontier Cancer Center
Billings, Montana, United States
- University of Rochester; Wilmot Cancer Institute Clinical Trials Office
Rochester, New York, United States
- University Hospital
Cleveland, Ohio, United States
- Oregon Health & Science University
Portland, Oregon, United States
- Prisma Health, Institute for Translational Oncology Research
Greenville, South Carolina, United States
- Baylor Research Institute
Dallas, Texas, United States
- Md Anderson Cancer Center
Houston, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Oct 2014
- Primary completion
- 30 Sept 2021
- Completion
- 30 Sept 2021
- Last update posted
- 22 Aug 2022
- Registered enrollment
- 21
- Registry id
- NCT02267863
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.